HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced that it has entered into a formal marketing agreement with Dr. James Forsythe, MD, HMD, board certified oncologist and a member of HST Global Inc.’s Board of Directors and Scientific Advisory Board.
According to the agreement, Dr. Forsythe and HST Global will be working together to manufacture, market and sell Dr. Forsythe’s Technologies under the trademark “FIT”. HST Global will be allowed to employ Dr. Forsythe’s image, expertise and related intellectual property. HST Global has acquired an exclusive license to manufacture, market and sell these products throughout the world and has obtained the exclusive right to use Dr. Forsythe’s identification and endorsement in connection with the marketing, sale and distribution of the FIT Technology Products.
Mr. Ron Howell, CEO and President of HST Global, Inc., stated, “This agreement significantly expands the relationship developed with Dr. Forsythe over the past two years. The company is poised to experience growth in 2010 through our current Wellness Clinic development strategies in Ecuador and Panama coupled with the marketing and sales of our line of nutraceutical products. The company continues to place emphasis on efforts to provide a growing world population with alternative integrative science-based products and treatments.”
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.